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Oncostatin M (OSM) is a multifunctional gp130 cytokine.
Although OSM is produced in adipose tissue, it is not produced
by adipocytes. OSM expression is significantly induced in adi-
pose tissue from obese mice and humans. The OSM-specific
receptor, OSM receptor  (OSMR), is expressed in adipocytes,
but its function remains largely unknown. To better understand
the effects of OSM in adipose tissue, we knocked down Osmr
expression in adipocytes in vitro using siRNA. In vivo, we gen-
erated a mouse line lacking Osmr in adiponectin-expressing
cells (OSMRFKO mice). The effects of OSM on gene expression
were also assessed in vitro and in vivo. OSM exerts proinflam-
matory effects on cultured adipocytes that are partially rescued
by Osmr knockdown. Osm expression is significantly increased
in adipose tissue T cells of high fat-fed mice. In addition, adi-
pocyte Osmr expression is increased following high fat feeding.
OSMRFKO mice exhibit increased insulin resistance and adipose
tissue inflammation and have increased lean mass, femoral
length, and bone volume. Also, OSMRFKO mice exhibit in-
creased expression of Osm, the T cell markers Cd4 and Cd8, and
the macrophage markers F4/80 and Cd11c. Interestingly, the
same proinflammatory genes induced by OSM in adipocytes are
induced in the adipose tissue of the OSMRFKO mouse, suggest-
ing that increased expression of proinflammatory genes in adi-
pose tissue arises both from adipocytes and other cell types.
These findings suggest that adipocyte OSMR signaling is
involved in the regulation of adipose tissue homeostasis and
that, in obesity, OSMR ablation may exacerbate insulin resis-
tance by promoting adipose tissue inflammation.
Adipose tissue (AT)3 plays an important role in the mainte-
nance of systemic metabolic homeostasis. Adipokine produc-
tion is a critical AT function and is highly regulated in several
physiological and pathological conditions, including AT expan-
sion, insulin resistance, obesity, and type 2 diabetes. Obesity is
closely associated with a chronic, low grade inflammatory state
characterized by macrophage infiltration of AT and subsequent
proinflammatory adipokine expression (1, 2). Adipokine mod-
ulation has been shown to be a key contributor to the insulin
resistance often observed in obesity.
Cytokines in the interleukin-6 (IL-6)/gp130 family include
IL-6, IL-11, leukemia inhibitory factor, cardiotrophin-1, ciliary
neurotrophic factor, and oncostatin M (OSM) (3). The gp130
cytokines regulate several physiological and biological pro-
cesses (4), and some of these cytokines, namely IL-6 and ciliary
neurotrophic factor, have profound effects on metabolism and
as such have been previous targets for obesity treatment (5– 8).
Although originally identified for its ability to inhibit tumori-
genesis (9), OSM modulates a host of other biological processes
that are cell type-dependent (10). Elevated OSM levels have
been observed in a variety of inflammatory diseases in humans,
including rheumatoid arthritis and atherosclerosis (11, 12).
OSM also has important roles in hepatic insulin resistance and
steatosis (13), inflammation (14), and cardiomyocyte remodel-
ing (15) and has several well characterized actions in the liver
(16 –18). Unlike other gp130 cytokines, OSM has its own spe-
cific receptor subunit (OSM receptor ; hereafter referred to as
OSMR) that heterodimerizes with gp130 to create the func-
tional OSM receptor complex, and this complex is responsible
for the majority of OSM effects (19).
Adipocytes and AT are highly responsive to OSM (20), and
Osmr is highly expressed in AT compared with other tissues
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sion occurs in AT of obese mice and humans (22). OSM is not
produced by adipocytes but is made in cells comprising the
stromal vascular fraction (SVF) of human AT (22). We have
shown that OSM is expressed in AT macrophages (22) in mice,
and others have shown that OSM is produced in liver Kupffer
cells where it contributes to steatosis and insulin resistance
(13). The majority of studies support a role for OSM in promot-
ing metabolic dysfunction. For example, it is well documented
that OSM inhibits adipogenesis (23, 24). In addition, OSM
induces plasminogen activator inhibitor-1 (PAI-1) expression
in murine adipocytes (22) and in human AT (25). PAI-1 is a
known player in metabolic dysfunction (26, 27). Despite a large
number of studies showing associations among OSM, inflam-
mation, and metabolic dysfunction, three recent reports from
the same group have suggested that OSM is a potential agent for
obesity treatment (21, 28, 29). Hence, there is currently a great
deal of confounding data on the role of OSM in obesity and
metabolic disease states. We have generated a mouse model,
the adipocyte-specific Osmr knock-out mouse (OSMRFKO), in
an attempt to clarify the function of AT OSM. To our surprise,
the loss of adipocyte OSM signaling in vivo was associated with
inflammation and insulin resistance. The interpretation of
these results is complicated by elevated AT OSM expression in
the OSMRFKO mice. Nonetheless, these results suggest that
intact adipocyte OSM signaling plays a role in the maintenance
of AT homeostasis.
Results
Increased Proinflammatory Adipokine and OSM Receptor
Subunit Expression in OSM-exposed Adipocytes—To under-
stand the function of OSM on adipocytes, we examined the
expression of several adipokines in 3T3-L1 adipocytes follow-
ing OSM exposure for the times indicated in Fig. 1. The expres-
sion levels of genes associated with insulin resistance and
inflammation (Pai1, tissue inhibitor of metalloproteinases 1
(Timp1), monocyte chemoattractant protein 1 (Mcp1), insulin-
like growth factor-binding protein 3 (Igfbp3), and osteopontin/
secreted phosphoprotein 1 (Spp1)), and interestingly, expres-
sion of genes encoding the two subunits of the murine OSM
receptor signaling complex (gp130 and Osmr) were all strongly
and significantly induced by OSM treatment (Fig. 1, A and B,
respectively). These results demonstrate that OSM can induce
the expression of its own receptor subunits as well as that of
several proinflammatory adipokines in cultured adipocytes.
Attenuation of Proinflammatory Adipokine Expression and
OSMR Expression and Function with Osmr Knockdown—To
further assess OSM signaling and the role of OSMR, 3T3-L1
adipocytes were transiently transfected with siOsmr or non-
targeted siRNA. Next, adipocytes were treated with OSM or
vehicle for 3– 4 h, and the expression levels of OSM-responsive
genes were examined. We obtained significant knockdown
(60%) of Osmr mRNA using this gene silencing method (Fig.
2A). Adipocytes transfected with siOsmr exhibited decreased
OSMR expression along with decreased OSMR signaling as
indicated by decreased phosphorylation of the OSM-induced
transcription factor STAT5 (Fig. 2B). The ability of OSM to
induce the expression of the proinflammatory adipokines
Timp1, Mcp1, and Il6 was attenuated in Osmr knockdown adi-
pocytes (Fig. 2C). As expected, expression levels of both gp130
and Osmr were significantly decreased in Osmr knockdown
cells exposed to OSM. However, no significant changes in
FIGURE 1. Chronic OSM exposure increases proinflammatory adipokine expression and induces expression of both subunits of the OSM receptor
complex in adipocytes. Relative mRNA levels in 3T3-L1 adipocytes exposed to murine OSM or vehicle (Veh) for the times indicated were measured by qRT-PCR.
Genes associated with adipose tissue insulin resistance and inflammation (Timp1, Mcp1, Igfbp3, Pai1, and Spp1) (A) and the OSM receptor signaling complex
(gp130 and Osmr) (B) were examined. Differences in expression levels as compared with vehicle-treated cells were analyzed with a Student’s t test. p values are
represented with letters (a, p  0.0001; b, p  0.001; c, p  0.01 versus vehicle-treated cells), and error bars represent S.D. Values reported represent results from
two independent experiments with each treatment condition performed in triplicate. , minutes.
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expression of IL-6 receptor  (Il6ra) or leukemia inhibitory
factor receptor (Lifr), two other gp130 family receptors, were
observed (Fig. 2D). These results suggest that 1) OSM can
directly induce expression of proinflammatory adipokines in
adipocytes via the OSMR signaling complex and 2) intact
OSMR signaling is required in part for transcriptional regula-
tion of both OSMR subunits.
Osm and Osmr Are Differentially Expressed among AT Cell
Types—We previously demonstrated in subcutaneous AT from
obese humans that the high levels of OSM originated from SVF
cells and that OSM was not expressed in human adipocytes
(22). In ob/ob mice, we previously observed that Osm expres-
sion in AT was readily detectable in macrophages (22). We
extended our previous findings by examining the expression of
Osm and Osmr in epididymal AT cell types (adipocytes, T cells,
and B cells) from C57BL/6J (B6) mice fed low fat diet (LFD) or
high fat diet (HFD) for 18 weeks. Compared with LFD-fed mice,
HFD-fed mice exhibited a significant increase in T cell Osm
levels (Fig. 3A), suggesting that some of the increased AT OSM
in obesity is derived from T cells. Increased Osm expression is
also observed in adipocytes from HFD-fed mice, which may be
due to the presence of lipid-laden macrophages in the adipocyte
fraction because adipocytes do not express Osm. Lastly, Osmr
expression is increased in adipocytes of HFD-fed mice,
although this increase is not significant (Fig. 3B).
Obese OSMRFKO Mice Exhibit Increased Fat-free Mass and
Are Insulin-resistant—To delete Osmr in adipocytes, we
obtained mice from The Jackson Laboratory where exon 2 (first
coding exon) of the Osmr gene was flanked by loxP sites (floxed;
OSMRfl/fl). Floxed mice were crossed with mice expressing Cre
recombinase under control of the adiponectin (Adipoq) gene
promoter (30). OSMRFKO mice exhibited decreased Osmr
expression in whole AT, but no changes in gene expression in
other tissues, including liver and spleen, were observed (Fig.
4A). Decreased Osmr gene expression was restricted to adi-
pocytes and not SVF cells (Fig. 4B). Decreased OSMR protein
expression in the adipocyte fraction from OSMRFKO AT is
shown in Fig. 4C.
After verification of knock-out specificity, OSMRFKO and
floxed control mice were fed HFD for 24 weeks. Although body
FIGURE 2. Osmr knockdown in 3T3-L1 adipocytes partially attenuates OSM-induced proinflammatory adipokine expression. A, relative Osmr mRNA
levels were measured by qRT-PCR to determine siOsmr efficacy. B, protein levels of OSMR and phosphorylated STAT5 were measured in 3T3-L1 adipocytes
transfected with non-targeting (NT) siRNA or siOsmr and subsequently treated with OSM for 10 min. Abundance of mRNA for OSM-responsive genes associated
with adipose tissue inflammation and insulin resistance (C) and various gp130 cytokine receptors (D) was assessed using qRT-PCR. For C and D, p values are
represented with asterisks (*, p  0.05; ***, p  0.001; ****, p  0.0001 versus non-targeting siRNA  OSM), and error bars represent S.D. Differences in
expression levels were analyzed with a Student’s t test. Values reported represent results from two independent experiments with each treatment condition
performed in triplicate. KD, knockdown.
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weights for OSMRFKO mice were slightly higher starting at
week 4 on HFD, the trend did not reach significance until 12
weeks of HFD feeding (Fig. 4D). The increased body weight of
OSMRFKO mice was mainly attributed to increased lean mass as
no significant differences in fat mass were observed between
the groups (Fig. 4E). Interestingly, significant differences in lean
mass of OSMRFKO mice were observed starting around 8 weeks
of HFD feeding prior to the slight divergence in body weight
(Fig. 4E). This difference in lean mass could possibly be attrib-
uted to increased bone mass as the mean nasoanal length of the
OSMRFKO mice was significantly greater than that of the con-
trol mice at the end of the study (10.9  0.075 versus 10.5 
0.053 cm, respectively; p  0.0043). After 24 weeks of HFD,
OSMRFKO mice had higher serum insulin (Fig. 5A), lower
serum total adiponectin levels (Fig. 5B), and blunted responses
to an insulin bolus during an insulin tolerance test (Fig. 5C),
suggesting impaired insulin-stimulated whole-body glucose
handling in these mice. A trend toward impaired glucose dis-
posal capacity was also observed during a glucose tolerance test,
although the trend was not significant (Fig. 5D).
Disrupted AT Homeostasis in Obese OSMRFKO Mice without
Any Alterations in Adipocyte Size or Liver Fat—Histological
assessment of epididymal AT in obese OSMRFKO and control
mice revealed an apparent increase in the presence of crownlike
structures (Fig. 6A), a hallmark of AT inflammation. However,
no changes in mean adipocyte area or size were observed
FIGURE 3. Expression and regulation of Osm and Osmr in AT cell types. Relative Osm mRNA levels (A) and relative Osmr mRNA levels (B) were measured in
the floating adipocyte fraction and in immune cells isolated from SVF from mice fed HFD or LFD for 18 weeks. Differences in expression levels were analyzed
with a Student’s t test. p values are represented with asterisks (*, p  0.05; ***, p  0.01 versus same cell type in LFD mice), and error bars represent S.D. Results
are representative of three independent experiments.
FIGURE 4. Mice with adipocyte-specific Osmr deficiency (OSMRFKO) have increased weight gain and increased fat-free mass. The genotype of OSMRFKO
mice was confirmed by qRT-PCR analysis of Osmr mRNA in whole tissues (A), qRT-PCR in adipocytes and SVF from fractionated AT (B), and Western blotting in
adipocytes from fractionated AT (C). Adipocyte-specific ablation of Osmr increases weight gain (D) and fat-free mass accumulation (circles) with no change in
fat mass (triangles) in mice on HFD (E). In the panels, gray bars and shapes represent OSMRFKO mice, and black bars and shapes represent OSMRfl/fl mice. Western
blots are representative of at least two independent experiments. Differences in gene expression levels, body weights, and NMR values between genotypes at
each time point were analyzed using a Student’s t test. p values are represented with asterisks (*, p  0.05; **, p  0.01 versus OSMRfl/fl), and error bars represent
S.D. n  8 for OSMRFKO mice, and n  10 for OSMRfl/fl mice. AU, arbitrary units; iWAT, inguinal white adipose tissue; eWAT, epididymal white adipose tissue.
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between OSMRFKO and control mice (Fig. 6, B and C, respec-
tively). In further support of an elevated inflammatory response
in OSMRFKO mice, significant increases in the expression of
macrophage markers (F4/80 and Cd11c) and T cell markers
(Cd4 and Cd8) were observed as well as a trend toward in-
creased expression of several proinflammatory cytokines
FIGURE 5. OSMRFKO mice exhibit impaired whole-body insulin response. Osmr-deficient mice have higher serum insulin levels (A) and lower serum
adiponectin levels (B) after a 4-h fast. There is a significantly decreased whole-body response to an insulin bolus (C) and a trend toward a decreased response
to a glucose bolus (D) in the OSMRFKO mice. For statistical analysis of serum values, a Student’s t test was used. For analysis of blood glucose values over time
as measured in the insulin tolerance test and glucose tolerance test, repeated measures analysis of variance was used with a Bonferroni post-test. p values are
represented with asterisks (*, p  0.05; **, p  0.01; ***, p  0.001 versus OSMRfl/fl), and error bars represent S.D. n  8 for OSMRFKO mice, and n  8 for OSMRfl/fl
mice.
FIGURE 6. OSMRFKO mice exhibit increased crownlike structure formation but no significant changes in adipocyte size. A, representative H&E sections
of epididymal fat from obese control and OSMRFKO mice. Scale bars, 250 m. Shown are average adipocyte area (B) and size distribution (C) of epididymal
adipocytes in control and OSMRFKO mice after 6 months of HFD. Error bars represent S.D. n  8 for OSMRFKO mice, and n  10 for OSMRfl/fl mice.
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(including Osm, tumor necrosis factor  (Tnfa), and Il6) (Fig.
7A). Of note, differential expression of extracellular matrix-
associated genes was observed in OSMRFKO mice, including
significant increases in expression of Timp1, fibronectin 1
(Fn1), and transforming growth factor 2 (Tgfb2). However,
there were no substantial changes in the expression of collagens
or most matrix metalloproteinases (Mmps; Fig. 7B). Interest-
ingly, the most striking changes in gene expression were
observed in Mmp7 and E-cadherin (Cdh1), two genes not nor-
mally considered to have major roles in AT (Fig. 7B).
Furthermore, quantitative measurements revealed no signif-
icant differences in hepatic triglyceride content between geno-
types (Fig. 8A). Similar results were found upon histological
evaluation of liver sections (Fig. 8B).
A Novel Bone Phenotype in OSMRFKO Mice—A significant
increase in femoral length (Fig. 8C) was identified in OSMRFKO
mice. Trabecular bone within the distal femur was also
increased (Fig. 8D); however, this change was not significantly
different (p  0.058). This change in bone volume density
appears to be related to an overall increase (p  0.050) in tra-
becular number in the OSMRFKO mice. In addition, trabecular
bone structure model index was significantly different where
the OSMRFKO mice had significantly more platelike trabeculae
(p  0.021).
Discussion
In this study, we assessed the direct effects of OSM on adi-
pocytes in vitro and characterized the phenotype of a mouse
that lacked OSMR in adiponectin-expressing cells (OSMRFKO
mouse). We used our newly generated mouse model to assess
the role of adipocyte OSMR in AT homeostasis and metabolic
health. Our results demonstrate that OSM treatment of cul-
tured adipocytes leads to a sustained increase in the expression
of several proinflammatory adipokines associated with insulin
resistance (Timp1, Mcp1, Pai1, Igfbp3, and Spp1). These obser-
vations are consistent with other studies that have shown ele-
vated Mcp1and Pai1 expression with OSM treatment in other
cell types, including fibroblasts and hepatic cells (31, 32). In
murine adipocytes, we have shown similar effects with acute
OSM treatment (22). The roles of MCP1 and PAI-1 in obesity,
inflammation, and fibrosis are well documented (for reviews,
see Refs. 26, 27, and 33).
Our novel finding that OSM treatment induces Timp1,
Igfbp3, and Spp1 expression in adipocytes is notable as dysregu-
lated expression of these genes is associated with insulin resis-
tance and metabolic dysregulation in vitro and in vivo (34 –39).
In obesity, AT Timp1 significantly increases (38, 39), and mice
injected with TIMP1 develop insulin resistance and systemic
fatty acid overload (38). IGFBP3-treated adipocytes exhibit
insulin resistance (36), and mice overexpressing Igfbp3 exhibit
decreased glucose uptake in AT and muscle (37). Mice lacking
Spp1 (osteopontin) are less likely to develop obesity and insulin
resistance and exhibit less AT macrophage infiltration (34, 35).
The ability of OSM to promote the expression of these para-
crine and endocrine mediators that favor insulin resistance
reveals a possible mechanism whereby OSM perpetuates AT
inflammation in obesity (see Fig. 9).
We previously reported increased OSM expression in AT
from obese rodents and humans and demonstrated that AT
OSM is produced from SVF cells and not from adipocytes (22).
We also observed expression of Osm gene expression in AT
macrophages from lean and ob/ob mice; however, the expres-
sion levels of Osm in AT macrophages were not significantly
altered in obesity (22). Our current observations extend those
findings by confirming that Osm expression in AT macro-
FIGURE 7. OSMRFKO mice exhibit increased inflammatory marker expression and altered expression of extracellular matrix-related genes in epidid-
ymal AT. Relative mRNA levels of inflammatory markers (A) and extracellular matrix-associated genes (B) in control and FKO epididymal fat were assessed by
qRT-PCR. Differences in gene expression levels between genotypes were analyzed using a Student’s t test. p values are represented with asterisks (*, p  0.05;
**, p  0.01 versus OSMRfl/fl), and error bars represent S.D. n  8 for OSMRFKO mice, and n  8 for OSMRfl/fl mice.
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phages is not altered by HFD feeding. However, we observed
that T cells also express Osm, and its expression is significantly
increased in AT by HFD feeding (Fig. 3). Furthermore, we dem-
onstrate that adipocyte Osmr expression is highly up-regulated
in HFD feeding. It is widely accepted that T cell recruitment
into AT (and subsequent activation) is a hallmark of the
chronic, low grade inflammation observed in obesity (40, 41)
and that activated T cells can produce OSM (42, 43). For the
first time, we demonstrate that AT Thy1.2 T cells express
Osm and that HFD induces T cell Osm expression in epididymal
AT.
OSM produces a proinflammatory response in cultured adi-
pocytes, and AT Osm expression is elevated in obese mice and
humans. These facts, coupled with data demonstrating
increased adipocyte Osmr expression following HFD feeding,
support the hypothesis that adipocyte Osmr knockdown and
concomitant reduction of adipocyte OSM signaling in vivo
could have metabolically favorable effects in obesity. We tested
this hypothesis by creating and phenotyping the OSMRFKO
mouse. Contrary to our hypothesis, OSMRFKO mice are less
metabolically healthy following chronic HFD feeding. OSMR-
FKO mice have modest increases in body mass and fat-free mass
with no significant changes in fat mass (Fig. 4) and exhibit sys-
temic insulin resistance and AT inflammation. Whole-body
Osmr KO mice fed a HFD have higher food intake, body mass,
and fat mass than controls with no differences in lean mass (21).
These mice also exhibit higher serum leptin and insulin levels
than control mice, no significant differences in serum adi-
ponectin levels, and hyperlipidemia when fed HFD for only 8
weeks (21). Our OSMRFKO mice also exhibited elevated insulin
levels but had lower adiponectin levels after 24 weeks of HFD
feeding. It is important to note that after 8 weeks of HFD feed-
ing divergence of the body weights of our control OSMRFKO
mice had not yet occurred. However, at this stage in the whole-
body KO mice, severe metabolic effects in AT, liver, pancreas,
and skeletal muscle were already observed, a fact that under-
scores the non-AT-specific effects in these mice (21). Although
the whole-body KO mice exhibited severe hepatic steatosis, we
did not observe any notable differences in liver triglyceride
between OSMRFKO and control mice (Fig. 8A). Osmr has well
known critical roles in liver development and hematopoiesis
(16, 45) and is expressed in many tissues during both embryonic
development and adulthood in mice (46); thus, it is not surpris-
ing that the phenotype of whole-body Osmr KO mice is more
severe and quite different from OSMRFKO mice.
The two major phenotypes of the OSMRFKO mice are AT
inflammation that is accompanied by increased AT OSM and
systemic insulin resistance. Unlike the whole-body KO mice,
OSMRFKO mice had no significant changes in fat mass or adi-
pocyte size despite increased proinflammatory and profibrotic
FIGURE 8. OSMRFKO mice have no changes in liver fat but exhibit a bone phenotype. Mean liver triglyceride (TG) levels (A) and representative H&E sections
of livers (B) from obese control and OSMRFKO mice are shown. Scale bars, 250 m. Mean femoral length (C) and mean bone volume/total volume (BV/TV) (D) for
obese control and OSMRFKO mice fed HFD for 6 months are shown. Differences in triglyceride levels and bone parameters between genotypes were analyzed
using a Student’s t test. p values are represented with asterisks (**, p  0.01 versus OSMRfl/fl), and error bars represent S.D. E, midcoronal views of three-
dimensional reconstructions of femora from representative control (right) and OSMRFKO (left) mice demonstrating increased trabecular bone in the distal
metaphysis of the femur of the OSMRFKO mice. Scale bar, 1 nm. For liver and bone measurements, n  9 for OSMRFKO mice, and n  8 for OSMRfl/fl mice.
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tissue profiles. These results suggest that loss of adipocyte
OSMR signaling negatively alters the AT adipokine profile and
influences the development of AT inflammation and insulin
resistance without altering the ability of AT to store lipid. Sur-
prisingly, many of the proinflammatory adipokines directly
induced by OSM in adipocytes in vitro were also induced in the
AT of OSMRFKO mice.
Another notable observation in the OSMRFKO mice was the
significant induction of Mmp7 in visceral adipose tissue. This
gene has not been well studied in the context of adipose tissue
or obesity but serves diverse functions in the innate immune
response (47). Although Mmp7 has known roles in tissue fibro-
sis (48), wound healing, and cell migration (47), its exact func-
tion in AT remains to be elucidated. A recent report describes a
significant induction of Mmp7 expression in subcutaneous AT
from obese, insulin-resistant humans when compared with
obese, insulin-sensitive humans (49). Future studies will focus
on the relationship of Mmp7 to adipocyte OSM signaling and
AT inflammation in obesity.
The elevated AT OSM levels observed in the OSMRFKO mice
(Fig. 7) support the notion that disrupting the paracrine actions
of OSM on adipocytes may contribute to the observed elevation
of AT OSM that may influence its paracrine actions on AT SVF
cells to promote further proinflammatory adipokine produc-
tion and thereby further disrupt AT homeostasis (Fig. 9). The
concept that intact adipocyte inflammatory signaling pathways
are both a requirement and adaptation for AT during obesity is
not new as similar requirements for TNF and other inflamma-
tory mediators have recently been demonstrated (50). Mice
expressing an adipocyte-specific dominant negative form of
TNF that cannot productively engage the TNF receptor are
severely glucose-intolerant and have decreased serum adi-
ponectin (50). Similarly, the adipocyte-specific receptor inter-
nalization and degradation (RID) complex transgenic mouse
has decreased proinflammatory signaling, is glucose-intolerant,
and exhibits hepatic steatosis (50). Although further studies are
needed, our results support a model where inhibition of adi-
pocyte OSM signaling leads to elevated OSM that likely has
paracrine effects on T cells that have high levels of Osmr expres-
sion (Fig. 3). However, the elevated expression of Osm and
Osmr on T cells in obesity coupled with the increased Cd4 and
Cd8 expression we observed in AT of OSMRFKO mice (Fig. 7)
greatly enhances the complexity and interpretation of the phe-
notype of the OSMRFKO mice. Future studies will be needed to
elucidate the role of T cell-derived OSM in the context of met-
abolic disease states.
Taken together, our novel results demonstrate a direct pro-
inflammatory effect of OSM on adipocytes and suggest that
abrogation of adipocyte OSM signaling disrupts AT homeosta-
sis to result in inflammation and insulin resistance in the
absence of any substantial changes in fat mass. These results
reveal a role of OSM in AT and the requirement for intact
adipocyte OSM signaling in the maintenance of metabolic
health in obesity. Additional research will be required to deter-
mine whether the phenotype of OSMRFKO mice is mediated by
FIGURE 9. Proposed physiological and pathological roles of OSM action in AT. At physiological OSM concentrations, such as those found in lean mice, OSM
produced by macrophages and other immune cells signals in a paracrine manner on adipocytes and other cell types to maintain AT homeostasis. In obese
HFD-fed mice, the population of AT immune cells changes and is associated with an increase in OSM from non-adipocyte cells. Elevated OSM in AT, acting in
part via OSMR on adipocytes, correlates with increased adipocyte expression of insulin resistance-promoting adipokines. In obese OSMRFKO mice, OSM is
unable to signal in a paracrine manner on adipocytes. However, the increased AT OSM appears to function as a paracrine or autocrine mediator in other AT cell
types, particularly in immune cells, to promote further AT inflammation.
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elevated OSM production in AT and/or altered immune cell
OSM signaling in various AT depots.
Experimental Procedures
Cell Culture and Treatments—Murine 3T3-L1 preadipocytes
were grown to 2 days postconfluence in DMEM with 10%
bovine serum and differentiated as described previously (22).
One day prior to beginning the treatment protocol in adi-
pocytes, medium was replaced with DMEM containing 5% FBS.
Cells were treated for 24 –120 h with 1 nM OSM (R&D Systems)
or vehicle (0.1% BSA in PBS) as indicated. During the treatment
period, culture medium was changed every 48 h. At the conclu-
sion of the treatment period, medium was removed, and cells
were washed with PBS and then harvested for RNA or protein
extraction.
Animals and Diets—Osmr floxed mice were obtained from
The Jackson Laboratory (stock number 011081). In these mice,
the first coding exon in the Osmr gene (exon 2) is flanked by
loxP sites. Adipoq-Cre mice were obtained from a Pennington
Biomedical Research Center colony that was originally gener-
ated by crossing hemizygous Cre mice (The Jackson Laboratory
stock number 010803) to B6 mice. These two mouse strains
were crossed to create the adipocyte-specific OSMR knock-out
mouse (Osmr flox/flox; Adipoq-Cre; OSMRFKO) and littermate
floxed controls (Osmr flox/flox; OSMRfl/fl). In some experi-
ments, C57BL/6J (B6) mice obtained directly from The Jackson
Laboratory were used as indicated. Animals were housed in a
temperature (22  2 °C)- and humidity-controlled (45–55%)
room under a 12-h light/dark cycle. Mice were allowed ad libi-
tum access to food and water, and body weights were measured
weekly. For HFD experiments in OSMRFKO mice, a purified
diet containing 45% of calories from fat was used (Research
Diets, number D12451). For HFD experiments in B6 mice, a
purified diet containing 60% of calories from fat was used
(Research Diets, number 12492). All experiments were
approved by the Pennington Biomedical Research Center Insti-
tutional Animal Care and Use Committee.
Animal Procedures and Serum Analyses—For studies on
OSMRFKO mice and controls, non-fasting body composition
was analyzed by NMR (Bruker LF50, Bruker Optics, Germany)
at baseline and every other week for the duration of the study
(51, 52). Body weights were obtained weekly. Intraperitoneal
insulin tolerance tests were performed on mice in the fed state
using i.p. injections of 0.04 unit of insulin/mouse (Humulin-R,
Eli Lilly). Intraperitoneal glucose tolerance tests were per-
formed after a 4-h fasting period using i.p. injections of 20%
dextrose. Tail glucose was measured at baseline (time 0) prior
to the administration of insulin or glucose and at the indicated
postinjection time points as described previously (51, 52). At
study end, blood was collected via cardiac puncture, centri-
fuged at 3500 rpm for 15 min at 4 °C, and serum was removed
and stored at 	80 °C until analyzed. ELISA kits were used for
the measurement of fasting serum insulin levels (Crystal Chem)
and fasting adiponectin levels (Millipore) according to the
manufacturers’ instructions.
For microcomputed tomography and histological analyses of
bone and bone marrow, intact hind limbs from a second cohort
of HFD-fed OSMRFKO (n  9) and littermate controls (n  8)
were collected, fixed in 10% neutral buffered formalin, and
stored in 70% ethanol. Femora were disarticulated and dis-
sected free from surrounding soft tissue.
AT Isolation and Fractionation—Isolation and fractionation
of epididymal or inguinal AT were performed as described pre-
viously in detail (53). For OSMRFKO and control mice, floating
adipocytes and SVF were processed for RNA or protein extrac-
tion. For HFD- and LFD-fed mice, the floating adipocyte frac-
tion and SVF were separated by collagenase digestion, and
immune cells from the SVF (Thy1.2 T cell, CD19 B cell,
F4/80 macrophage) were isolated sequentially by positive
selection using magnetic beads. Briefly, positive isolation of T
cells was performed using mouse pan-T (Thy1.2) Dynabeads
(Invitrogen) according to the manufacturer’s protocol. For pos-
itive isolation of B cells, the cell suspension was incubated with
biotinylated CD19 antibody (eBioscience, catalogue number
13-0193), and biotin-binding Dynabeads were used to select the
CD19 cells. Positive isolation of F4/80 macrophages was
performed by incubating cells with an F4/80 antibody (eBiosci-
ence, catalogue number 16-4801) and using IgG Dynabeads to
isolate the F4/80 cells. Cells remaining after the sequential
isolation of T cells, B cells, and macrophages were also col-
lected. RNA was isolated, and cDNA was prepared. Gene
expression was measured using qRT-PCR, and Ppib was used as
a control gene.
Adipocyte Area and Size Distribution—For determination of
average adipocyte size, hematoxylin- and eosin-stained epidid-
ymal AT sections were imaged using a Hamamatsu Nano-
Zoomer digital slide scanner at 20
 resolution. The resulting
images were subsequently analyzed and quantified using a cus-
tom application within VIS software version 5.0.5 (Visiop-
harm). The number of adipocytes counted per experimental
condition ranged from 1,498 to 6,693.
Immunoblotting—Proteins were separated on 5% polyacryl-
amide gels containing sodium dodecyl sulfate and transferred
to nitrocellulose membrane (Bio-Rad). After transfer, the
membrane was blocked and incubated with goat anti-OSMR
(R&D Systems, catalogue number AF662), rabbit anti-STAT5A
(Santa Cruz Biotechnology, catalogue number sc-1081), or
mouse anti-phospho-STAT5 (Millipore, catalogue number
05-495) primary antibodies overnight at 4 °C. Results were visu-
alized with the appropriate horseradish peroxidase-conjugated
secondary antibodies (Jackson ImmunoResearch Laboratories)
and enhanced chemiluminescence (Pierce).
Gene Expression Analyses—Total RNA was isolated from
cells or mouse tissues using an RNeasy Mini kit (Qiagen), and
yield was determined by spectrophotometry (NanoDrop
Technologies). cDNA synthesized for use with the Extracel-
lular Matrix and Fibrosis RT2 Profiler PCR Arrays (Qiagen)
was reverse transcribed using the RT2 First Strand kit (Qia-
gen) with the SYBR Green system. All other cDNA was syn-
thesized using the High Capacity cDNA Reverse Transcrip-
tion kit (Applied Biosystems) with the SYBR Green system.
Relative quantification of mRNA expression was analyzed
using an ABI Prism 7900 Sequence Detection System
(Applied Biosystems). Sequences for mouse primers not
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included in the targeted arrays (Integrated DNA Technolo-
gies) appear in Table 1.
Microcomputed Tomography and Histological Analyses of
Bone—Intact femora were placed in holders for scanning by
microcomputed tomography (Scanco Model 40, Scanco Medi-
cal AG, Basserdorf, Switzerland). Appropriate fluid (70% etha-
nol) was used so that bone density as well as bone volume could
be determined. The samples were scanned in a coronal plane at
55 kV, 0.3-s integration time, with a 10-m voxel size in plane
and a 10-m slice thickness. The lengths of the bones were
evaluated from the scans ranging from the most proximal por-
tion of the greater trochanter to the most distal aspect of the
femoral condyles. The regions of interest for tissue analyses
were determined to range from the distal 30% of the femur to
the distal physis for trabecular bone and midshaft (50% of the
length of the femur) for cortical bone. The proper thresholds
for both trabecular and cortical bone were tested, and the same
thresholds were used throughout the study. For trabecular
bone, bone volume, total volume, bone volume density; and
trabecular number, spacing, and thickness among other param-
eters were evaluated using standard procedures and nomencla-
ture (44).
Statistical Analyses—JMP Pro 12.0 and GraphPad Prism 5
software were used for all statistical analyses. Results are
expressed as mean  S.D. Differences between specified
groups were analyzed using the Student’s t test with results
considered significant when p was 0.05. Differences over
time were analyzed using repeated measures analysis of vari-
ance with a Tukey’s post hoc test or by Student’s t test at each
time point.
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